Latest On Oasmia Pharmaceutical AB (publ) (OASMY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-03-01 11:08 EST | News | Kazia grants global rights for ovarian cancer therapy to Oasmia | N/A |  |
| 2021-02-23 02:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-10 23:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-04 19:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 20:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-10 23:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-31 23:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 11:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 23:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 20:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 19:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-21 07:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 08:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-07 19:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 15:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 19:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 04:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 03:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 09:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 23:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 19:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-30 07:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 11:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 07:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 03:25 EST | Financials | Company financials have been released. | Neutral | |
About Oasmia Pharmaceutical AB (publ) (OASMY):
Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer that has completed phase III clinical trial, as well as in phase I clinical trial for the treatment of metastatic breast cancer; and Docetaxel micellar, a patented formulation of cytostatic docetaxel in combination with XR-17 that has completed pre-clinical trial for the treatment of prostate cancer. It also provides Doxophos, a patented formulation of cytostatic doxorubicin in combination with XR-17 Doxorubicin for the treatment of various forms of cancers, including blood, skeleton, breast, prostate, and lungs; and KB9520, a substance that is in pre-clinical stage to reduce the side effects of cytostatics treatment. In addition, the company's animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Additionally, its technology platform portfolio comprises XR-19, an internal technology, which is under assessment process for a dual encapsulation technology; and XR-17, a proprietary solubility-enhancing technology platform in oncology and other therapeutic areas. Oasmia Pharmaceutical AB (publ) was founded in 1988 and is headquartered in Uppsala, Sweden.
General
- Name Oasmia Pharmaceutical AB (publ)
- Symbol OASMY
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 29
- Fiscal Year EndApril
- Web URLhttp://www.oasmia.com
Valuation
- Price/Sales (Trailing 12 Mt.) 7.28
- Price/Book (Most Recent Quarter) 1.99
- Enterprise Value Revenue 0.74
Financials
- Most Recent Quarter 2020-10-31
- Return on Assets -3%
- Return on Equity -11%
- Revenue Per Share $0
- Gross Profit 27.14 million
- Quarterly Earnings Growth -75.3%
Highlights
- Market Capitalization 182.6 million
- Analyst Target Price $6
Share Statistics
- Shares Outstanding 149.46 million
- Shares Float 105.59 million
- % Held by Insiders <1%
- % Held by Institutions 0.05%
- Shares Short 20724
- Shares Short Prior Month 11075
- Short Ratio 0.03
Technicals
- Beta -0.15
- 52 Week High $2.87
- 52 Week Low $1.09
- 50 Day Moving Average 1.18
- 200 Day Moving Average 1.38
Dividends
- Forward Annual Dividend Yield 11.5%
- Dividend Date 2019-12-16
- ExDividend Date 2019-12-06
- Dividend Yield 0%
Oasmia Pharmaceutical AB (publ) (OASMY) Dividend Calendar:
OASMY's last dividend payment was made to shareholders on December 16, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Oasmia Pharmaceutical AB (publ) (OASMY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-10-31 | 2020-12-31 | $N/A | -$0.01 | ||
| 2020-07-31 | 2020-10-31 | $N/A | -$0.01 | ||
| 2020-04-30 | 2020-07-31 | $N/A | -$0.01 | ||
| 2020-01-31 | 2020-04-30 | $144000 | $0.02 | ||
| 2019-10-31 | 2020-01-31 | $252000 | -$0.02 | ||
| 2019-07-31 | 2019-10-31 | $182000 | -$0.01 | ||
| 2019-04-30 | 2019-07-31 | $266000 | -$0.01 | $0.00 | |
| 2019-01-31 | 2019-04-30 | $1.43 million | -$0.04 | ||
| 2018-10-31 | 2019-01-31 | $438088.38 | -$0.01 | ||
| 2018-07-31 | 2018-10-31 | $293094.04 | -$0.04 | ||
| 2018-04-30 | 2018-07-31 | -$0.02 | |||
| 2018-01-31 | 2018-04-30 | -$0.02 | |||
| 2017-10-31 | 2018-01-31 | -$0.02 | |||
| 2017-07-31 | 2017-10-31 | -$0.02 | |||
| 2017-04-30 | 2017-07-31 | -$0.03 | |||
| 2017-01-31 | 2017-04-30 | -$0.04 | -$0.07 | 43.14% | |
| 2016-10-31 | 2016-12-02 | -$0.05 | |||
| 2016-07-31 | 2016-09-02 | -$0.09 | |||
| 2016-04-30 | 2016-06-03 | -$0.08 | |||
| 2016-01-31 | 2016-03-03 | -$0.06 | |||
| 2015-10-31 | 2015-12-03 | -$0.11 |
Oasmia Pharmaceutical AB (publ) (OASMY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Oasmia Pharmaceutical AB (publ) (OASMY) Chart:
Oasmia Pharmaceutical AB (publ) (OASMY) News:
Below you will find a list of latest news for Oasmia Pharmaceutical AB (publ) (OASMY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Oasmia Pharmaceutical AB (publ) (OASMY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Oasmia Pharmaceutical AB (publ) (OASMY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|